Related Experiment Video
Updated: Jun 4, 2026
11:27
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles
Solmaz Ghaffari1, Jaleh Varshosaz, Afrooz Saadat
1Department of Pharmaceutics, Faculty of Pharmacy and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
International Journal of Nanomedicine
|February 4, 2011
Summary
Solid lipid nanoparticles (SLNs) offer a promising pulmonary delivery system for amikacin, potentially reducing dosage and toxicity. These amikacin SLNs demonstrated enhanced efficacy against Pseudomonas aeruginosa in vitro, suggesting improved safety and treatment outcomes.
Area of Science:
- Pharmaceutical Nanotechnology
- Drug Delivery Systems
- Antimicrobial Research
Background:
- Pulmonary infections often require prolonged amikacin treatment, increasing toxicity risks.
- Developing advanced drug delivery systems can mitigate amikacin's adverse effects.
- Solid lipid nanoparticles (SLNs) are a viable platform for targeted drug delivery.
Purpose of the Study:
- To design and characterize amikacin-loaded solid lipid nanoparticles (SLNs) for pulmonary administration.
- To evaluate the in vitro antimicrobial efficacy of amikacin SLNs against Pseudomonas aeruginosa.
- To assess the stability and release profile of lyophilized amikacin SLNs.
Main Methods:
- Amikacin SLNs were prepared using cholesterol via solvent diffusion and homogenization.
- Particle size, zeta potential, loading efficiency, and drug release were analyzed.
- Minimum inhibitory concentration (MIC) and minimum bacteriostatic concentration (MBC) were determined using broth macrodilution.
- Lyophilization with cryoprotectants was employed for enhanced SLN stability.
Main Results:
- Amikacin SLNs exhibited improved in vitro efficacy, with MIC and MBC values approximately two-fold lower than free amikacin.
- Lyophilization enhanced particle stability, with limited size increase and increased zeta potential (+17 mV).
- Higher storage temperatures accelerated amikacin release from SLNs.
Conclusions:
- Amikacin SLNs represent a potentially safer and more effective pulmonary drug delivery system.
- Reduced dosing frequency and lower toxicity are achievable with amikacin SLNs.
- Lyophilization improves the stability of amikacin SLNs for storage and potential clinical use.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...